ProSciento, Inc and Antaros to partner and launch functional imaging studies of cardiometabolic drug action

ProSciento, Inc and Antaros to partner and launch functional imaging studies of cardiometabolic drug action

closer lookProSciento, Inc and Antaros Medical recently announced a strategic collaboration to study the action of cardiometabolic drugs and drug candidates using PET/MRI imaging. The initiative will focus on diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH).

Read full article at Close Concerns »